The goal of the Biomaterials Development Center (BDC) is to reduce implant related infections by bringing a number of innovative infection-resistant biomaterials (or coatings) to clinical application
By formulating long-term, exclusive public-private partnerships with medical device or polymer companies, we can bring infection-resistant Biomaterials to clinical practice. Together we can overcome many of the key issues that have previously resulted in biomaterials being lost in translation from bench to bed (clinical application).
By combining the extensive knowledge, facilities and resources of the BDC together with the market knowledge, engineering skills and resources of a proven medical device/polymer company, we can jointly develop new infection-resistant materials and bring them to clinical application.
We invite major device or material companies to commit for 10 years to co-develop:
Exclusivity is limited to individual or combined fields
9700 RB Groningen,
Craig A. Grove PhD, Project manager
Tel: +31 (0)652724594
"Infection is the major cause of implant failure. On average, 5% of all biomaterial-implant patients experience severe complications, mainly due to infection."
More information and latest news on: biomaterialsgroningen.com